The correlation between HbA1c and depression scores is an increasingly recognised area of clinical importance in diabetes care. HbA1c — the blood marker reflecting average glucose levels over two to three months — is a key measure in managing type 1 and type 2 diabetes, whilst depression is disproportionately common in people living with long-term conditions. Research suggests a bidirectional relationship: poor glycaemic control may worsen mood, and depression can undermine diabetes self-management. Understanding this link has significant implications for integrated NHS care, helping clinicians identify when physical and mental health support should be delivered together.

Understanding the Link Between HbA1c and Depression

Higher HbA1c values are associated with greater depressive symptom severity, with the relationship considered bidirectional — poor glycaemic control may worsen mood, and depression can impair diabetes self-management.

HbA1c (glycated haemoglobin) is a blood marker used to assess average blood glucose levels over the preceding two to three months. It is a cornerstone measurement in the management of both type 1 and type 2 diabetes. Depression, meanwhile, is one of the most prevalent mental health conditions globally, and people living with long-term conditions such as diabetes are at significantly elevated risk of experiencing it, as acknowledged in NICE guidance on both diabetes (NG28, NG17) and depression (NG222).

Research has increasingly explored whether there is a meaningful correlation between HbA1c and depression scores — that is, whether higher HbA1c values (indicating poorer glycaemic control) are associated with greater severity of depressive symptoms. This relationship is thought to be bidirectional: poor blood glucose management may contribute to low mood, whilst depression itself can impair a person's ability to self-manage their diabetes effectively.

It is important to note that correlation does not imply causation. Whilst studies have identified statistical associations between elevated HbA1c and higher scores on validated depression rating tools — such as the PHQ-9 (Patient Health Questionnaire-9) — these tools support, but do not replace, a full clinical assessment and formal diagnosis. The precise mechanisms underpinning this relationship remain an active area of investigation. Understanding this link has significant implications for how diabetes care is delivered within the NHS, particularly in terms of integrating physical and mental health support.

What the Evidence Says: Key Research Findings

Meta-analyses show people with diabetes and depression have meaningfully higher HbA1c values than those without depression, though effect sizes vary and most studies are cross-sectional, limiting causal conclusions.

A growing body of peer-reviewed literature supports an association between elevated HbA1c levels and higher depression scores. A meta-analysis published in Diabetes Care found that individuals with diabetes who also had depression demonstrated significantly poorer glycaemic control compared to those without depression, with mean HbA1c values notably higher in the depressed group — with some analyses reporting differences in the region of 0.3–0.5 percentage points (approximately 3–5 mmol/mol), though effect sizes vary across studies. Longitudinal studies have also shown that persistent depressive symptoms can predict worsening HbA1c over time.

In the UK context, data from large primary care databases have reinforced these findings. People with type 2 diabetes and comorbid depression are more likely to have HbA1c values above NICE-recommended targets. NICE NG28 sets regimen-based targets: 48 mmol/mol (6.5%) for adults managed by lifestyle or a drug not associated with hypoglycaemia, and 53 mmol/mol (7.0%) for those on a drug associated with hypoglycaemia (such as a sulphonylurea or insulin). Individual targets should always be agreed between the person and their clinician. Some studies report a dose-dependent pattern — meaning that as depression severity increases (as measured by tools such as the PHQ-9 or the Hospital Anxiety and Depression Scale), HbA1c values tend to rise correspondingly, though this finding is not universal across all analyses.

It is worth acknowledging the limitations of existing research:

• Many studies are cross-sectional, limiting causal inference.

• Depression screening tools vary across studies, making direct comparisons difficult.

• Confounding variables — including socioeconomic deprivation, physical inactivity, and polypharmacy — may influence both HbA1c and depression scores independently.

Despite these caveats, the overall weight of evidence — including Cochrane reviews on depression management in diabetes — suggests that the correlation between HbA1c and depression scores is clinically meaningful and warrants routine attention in diabetes care settings.

How Poor Glycaemic Control May Affect Mental Health

Chronic hyperglycaemia may contribute to depression via pro-inflammatory cytokines, HPA axis dysregulation, microvascular complications, and the psychological burden of diabetes self-management demands.

Several biological and psychosocial pathways have been proposed to explain how elevated HbA1c and poor glycaemic control may contribute to depressive symptoms, though the evidence for individual mechanisms varies in quality and certainty. From a neurobiological standpoint, chronic hyperglycaemia is hypothesised to be associated with increased systemic inflammation, including raised levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). These inflammatory mediators are thought to disrupt neurotransmitter pathways — particularly serotonin and dopamine — that are central to mood regulation, though this remains an area of ongoing research.

Hyperglycaemia may also affect the hypothalamic-pituitary-adrenal (HPA) axis, potentially leading to dysregulated cortisol secretion. Elevated cortisol is associated with depressive disorders, and this hormonal disruption has been proposed as a mechanistic bridge between poor glycaemic control and low mood, though direct causal evidence in humans is limited. Additionally, the microvascular complications of poorly controlled diabetes — including peripheral neuropathy, retinopathy, and nephropathy — carry a significant psychological burden, contributing to feelings of hopelessness, reduced quality of life, and social withdrawal.

It is also important to recognise the impact of hypoglycaemia (low blood glucose) on mental health. Episodes of hypoglycaemia can cause acute anxiety, cognitive impairment, and low mood, and fear of hypoglycaemia may itself contribute to psychological distress and avoidance behaviours that worsen overall glycaemic management.

From a psychosocial perspective, the daily demands of diabetes self-management — monitoring blood glucose, adhering to dietary changes, managing medications, and attending regular appointments — can be exhausting and demoralising. This phenomenon, sometimes referred to as diabetes distress, is distinct from clinical depression but can overlap with it and contribute to rising HbA1c through reduced adherence. Validated tools such as the Problem Areas in Diabetes (PAID) scale or the Diabetes Distress Scale (DDS) can help clinicians assess distress separately from depression. Recognising the difference between diabetes distress and a formal depressive disorder is clinically important, as the management approaches differ, and NICE NG28 and NG17 both recommend that psychological and emotional difficulties are assessed and addressed as part of routine diabetes care.

Screening for Depression in People with Diabetes on the NHS

The PHQ-9 is the most widely used NHS tool for depression screening in diabetes; a score of 10 or above indicates moderate depression and warrants further clinical assessment.

NICE guidance (NG28: Type 2 diabetes in adults; NG17: Type 1 diabetes in adults; NG222: Depression in adults) recommends that healthcare professionals remain vigilant for psychological and emotional difficulties in people with diabetes, including depression and anxiety. Whilst NICE does not mandate a specific universal screening schedule for depression in all people with diabetes, it advises that practitioners use validated tools when psychological distress is suspected. It is important to note that these tools support, but do not replace, a full clinical assessment and formal diagnosis.

In NHS primary care, the PHQ-9 is the most widely used validated tool for depression screening and severity assessment. A score of 10 or above on the PHQ-9 is generally considered indicative of moderate depression and warrants further clinical assessment. The PHQ-2 (a two-question version) is often used as an initial brief screen. For anxiety, the GAD-7 is commonly employed alongside the PHQ-9.

Key triggers for depression screening in people with diabetes include:

• Persistently elevated HbA1c despite appropriate treatment intensification

• Repeated missed appointments or poor engagement with the diabetes care team

• Unexplained weight changes or disrupted sleep patterns

• Expressed feelings of hopelessness or reduced motivation to self-manage

The NHS Long Term Plan emphasises the importance of integrated physical and mental health care, and some Integrated Care Boards (ICBs) support co-located mental health practitioners within diabetes clinics, though availability varies by area. Annual diabetes reviews — structured around the NHS Nine Care Processes and Quality and Outcomes Framework (QOF) indicators, and monitored through the National Diabetes Audit — provide a structured opportunity to incorporate brief psychological screening alongside physical health checks.

Managing Both HbA1c and Depression Together

Treating depression in people with diabetes can produce modest but meaningful HbA1c improvements; SSRIs are preferred first-line antidepressants, whilst CBT and structured diabetes education also have supporting evidence.

Effective management of the relationship between HbA1c and depression requires a genuinely integrated approach that addresses both conditions simultaneously rather than in isolation. Evidence from Cochrane reviews and randomised controlled trials suggests that treating depression in people with diabetes can lead to modest but clinically meaningful improvements in HbA1c, and conversely, improving glycaemic control may alleviate some depressive symptoms, though effect sizes are variable.

From a pharmacological perspective, the choice of antidepressant in people with diabetes warrants careful, individualised consideration. Selective serotonin reuptake inhibitors (SSRIs) — such as sertraline and fluoxetine — are commonly used as first-line treatment for depression in this population. However, the metabolic and weight effects of SSRIs vary between individual agents and between patients; prescribers should not assume a class-wide neutral effect. Weight and glycaemic parameters should be monitored following initiation or dose change. In contrast, tricyclic antidepressants (TCAs) and some atypical antipsychotics used as augmentation agents are associated with weight gain and worsening glycaemic control, and should be used with caution in people with diabetes. Prescribers should consult the BNF and MHRA guidance — including relevant MHRA Drug Safety Updates on antipsychotics and metabolic risk — when initiating or adjusting antidepressant or antipsychotic therapy in people with diabetes. If you suspect that a medicine is causing side effects, these can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

Non-pharmacological interventions are equally important:

• Cognitive behavioural therapy (CBT), available via NHS Talking Therapies (formerly IAPT) in England, has demonstrated efficacy in both depression and diabetes distress, as supported by NICE NG222.

• Structured diabetes education programmes such as DESMOND (for type 2, per NICE NG28) and DAFNE (for type 1, per NICE NG17) can improve self-efficacy and reduce psychological burden.

• Physical activity, supported through social prescribing, has robust evidence for improving both HbA1c and mood.

A collaborative care model — where GPs, diabetes specialist nurses, dietitians, and mental health practitioners work in a coordinated manner — is considered best practice and is increasingly supported within NHS frameworks, in line with NICE NG222 recommendations for people with depression and a chronic physical health condition.

When to Seek Support from Your GP or Diabetes Team

Contact your GP or diabetes team promptly if you experience persistent low mood, difficulty managing your diabetes, or HbA1c consistently above your agreed target; self-referral to NHS Talking Therapies is available without a GP referral.

If you are living with diabetes and notice changes in your mood, motivation, or ability to manage your condition, it is important not to dismiss these as simply part of having a long-term illness. Both depression and poor glycaemic control are treatable, and early intervention leads to significantly better outcomes for both physical and mental health.

You should contact your GP or diabetes care team promptly if you experience:

• Persistent low mood, tearfulness, or feelings of hopelessness lasting more than two weeks

• Loss of interest in activities you previously enjoyed

• Difficulty concentrating, which is affecting your ability to manage your diabetes

• Significant changes in appetite, sleep, or energy levels

• HbA1c results that are consistently above your agreed target despite your best efforts

• Thoughts of self-harm or suicide — in which case, seek urgent support immediately

If you are in immediate danger, call 999 or go to your nearest A&E. For urgent mental health support that is not an emergency, contact NHS 111 (England, Scotland, and Wales) or your GP's out-of-hours service.

For non-urgent mental health support, you can self-refer to NHS Talking Therapies (formerly IAPT) in England without a GP referral, which offers CBT and other evidence-based psychological therapies. In Scotland, equivalent support is available through NHS Inform and local health boards. In Wales, contact NHS 111 Wales for guidance on local mental health services. In Northern Ireland, support is available through NI Direct and your local health and social care trust.

It is also worth raising concerns at your annual diabetes review, which is an ideal opportunity to discuss both your HbA1c results and your emotional wellbeing with your care team. Seeking mental health support is a positive step and will not negatively affect your diabetes care — addressing both aspects of your health together is the most effective path to long-term wellbeing. All information shared with your care team is treated in confidence in line with NHS confidentiality standards.

Frequently Asked Questions